Activity of the hypoxia-activated prodrug, TH-302, in preclinical human Acute myeloid leukemia models

Clinical Cancer Research

Volumn 19, Issue 23, 2013, Pages 6506-6519

  Portwood, Scott ^a   Lal, Deepika ^a   Hsu, Yung Chun ^a   Vargas, Rodrigo ^a   Johnson, Megan K ^a   Wetzler, Meir ^a   Hart, Charles P ^b   Wang, Eunice S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Threshold Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; CYTARABINE; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; N,N' BIS(2 BROMOETHYL)PHOSPHORODIAMIDIC ACID (1 METHYL 2 NITRO 1H IMIDAZOL 5 YL)METHYL ESTER; PIMONIDAZOLE; REACTIVE OXYGEN METABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG ACTIVITY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; LEUKEMIA CELL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; DNA FRAGMENTATION; FEMALE; HISTONES; HL-60 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, SCID; NITROIMIDAZOLES; PHOSPHORAMIDE MUSTARDS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; REACTIVE OXYGEN SPECIES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890289339     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0674     Document Type: Article

References (41)

1. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011;29:591-9.
2. Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, Lazzaretti M, et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1alpha overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138 (+) cells. Leukemia 2010;24:1967-70.
3. Fiegl M, Samudio I, Clise-Dwyer K, Burks JK, Mnjoyan Z, Andreeff M. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 2009;113:1504-12.
4. Harrison JS, Rameshwar P, Chang V, Bandari P. Oxygen saturation in the bone marrow of healthy volunteers. Blood 2002;99:394.
5. Chow DC, Wenning LA, Miller WM, Papoutsakis ET. Modeling pO (2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J 2001;81:685-96.
6. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007;104:5431-6.
7. Winkler IG, Barbier V, Wadley R, Zannettino AC, Williams S, Levesque JP. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood 2010;116:375-85.
8. Eliasson P, Jonsson J. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol 2010;222:17-22.
9. Giuntoli S, Rovida E, Gozzini A, Barbetti V, Cipolleschi MG, Olivotto M, et al. Severe hypoxia defines heterogeneity and selects highly immature progenitors within clonal erythroleukemia cells. Stem Cells (Dayton, Ohio) 2007;25:1119-25.
10. Schaefer C, Krause M, Fuhrhop I, Schroeder M, Algenstaedt P, Fiedler W, et al. Time-course-dependent microvascular alterations in a model of myeloid leukemia in vivo. Leukemia 2008;22:59-65.
11. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, et al. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One 2011;6:e23108.
12. Chen Y, Jacamo R, Shi YX, Wang RY, Battula VL, Konoplev S, et al. Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood 2012;119:4971-80.
13. Mortensen BT, Jensen PO, Helledie N, Iversen PO, Ralfkiaer E, Larsen JK, et al. Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br J Haematol 1998;102:458-64.
14. Iversen PO, Thing-Mortensen B, Nicolaysen G, Benestad HB. Decreased blood flow to rat bone marrow, bone, spleen, and liver in acute leukemia. Leuk Res 1993;17:663-8.
15. Jensen PO, Mortensen BT, Hodgkiss RJ, Iversen PO, Christensen IJ, Helledie N, et al. Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats. Cell Prolif 2000;33:381-95.
16. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
17. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008;8:967-75.
18. Giuntoli S, Rovida E, Barbetti V, Cipolleschi MG, Olivotto M, Dello Sbarba P. Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations. Leukemia 2006;20:1291-3.
19. Fiegl M, Samudio I, Mnjoyan Z, Korchin B, Fritsche H, Andreeff M. Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells. Leukemia 2010;24:1364-7.
20. Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SN, Starostik P, et al. Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res 2011;35:579-84.
21. Wellmann S, Guschmann M, Griethe W, Eckert C, Von Stackelberg A, Lottaz C, et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 2004;18:926-33.
22. Matsunaga T, Imataki O, Torii E, Kameda T, Shide K, Shimoda H, et al. Elevated HIF-1alpha expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy. Leuk Res 2012;36:e122-4.
23. Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, et al. Regulation of HIF-1alpha signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther 2012;13:858-70.
24. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res 2012;18:758-70.
25. Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther 2012;11:740-51.
26. Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Van De Broek I, et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 2010;116:1524-7.
27. Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, et al. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology 2011;80:50-6.
28. Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 2011;17:2997-3004.
29. Thomas D, Handisides DR, Lorente GA, Benito JM, Borthakur G, Jabbour E, et al. Phase 1 study of TH-302, a hypoxia activated cytotoxic prodrug, in subjects with advanced leukemia. J Clin Oncol 30, 2012 (suppl; abstr 6585).
30. Tanabe S, Zeleznik-Le NJ, Kobayashi H, Vignon C, Espinosa R III, LeBeau MM, et al. Analysis of the t (6;11) (q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients and in the ML-2 cell line. Genes Chromosomes Cancer 1996;15:206-16.
31. Lal D, Park JA, Demock K, Marinaro J, Perez AM, Lin MH, et al. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Mol Cancer Ther 2010;9:2737-51.
32. Desplat V, Faucher J, Mahon F, Dello Sbarba P, Praloran V, Ivanovic Z. Hypoxia modifies proliferation and differentiation of CD34 (+) CML cells. Stem Cells (Dayton, Ohio) 2002;20:347-54.
33. Hedley DW, McCulloch EA. Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2. Leukemia 1996;10:1143-9.
34. Zhou FL, Zhang WG, Wei YC, Meng S, Bai GG, Wang BY, et al. Involvement of oxidative stress in the relapse of acute myeloid leukemia. J Biol Chem 2010;285:15010-5.
35. Sallmyr A, Fan J, Datta K, Kim KT, Grosu D, Shapiro P, et al. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood 2008;111:3173-82.
36. Hole PS, Darley RL, Tonks A. Do reactive oxygen species play a role in myeloid leukemias? Blood 2011;117:5816-26.
37. Takubo K, Suda T. Roles of the hypoxia response system in hematopoietic and leukemic stem cells. Int J Hematol 2012;95:478-83.
38. Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, et al. Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011;57:443-53.
39. Hunter FW, Wang J, Patel R, Hsu HL, Hickey AJ, Hay MP, et al. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs. Biochem Pharmacol 2012;83:574-85.
40. Baumann RP, Ishiguro K, Penketh PG, Shyam K, Zhu R, Sartorelli AC. KS900: a hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O (6)-alkylguanine-DNA alkyltransferase in neoplastic cells. Biochem Pharmacol 2011;81:1201-10.
41. Hu J, Van Valckenborgh E, Dehui X, Menu E, De Raeve H, De Bruyne E, et al. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. Mol Cancer Ther Published Online First July 5, 2013.